Mar 06, 2020
European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
Jan 31, 2020
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
Jan 10, 2020
Technological Advancements Expand Biopharmaceuticals' Production Capabilities
Sep 26, 2019
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes
Apr 30, 2019
FDA approves first treatment for all genotypes of hepatitis C in pediatric patients
Nov 12, 2018
The Medicines Patent Pool Signs Licence with AbbVie to Expand Access to Key Hepatitis C Treatment, Glecaprevir/Pibrentasvir
Oct 11, 2017
AbbVie Demonstrates Leadership in HCV with New MAVYRET(TM) (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017
Sep 27, 2017
AbbVie Announces Approval of MAVIRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan
Aug 03, 2017
AbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
Jul 28, 2017
European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Jun 23, 2017
AbbVie Receives CHMP Positive Opinion for MAVIRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)